Download PDF
Der Klinikarzt 2004; 33(3): 58-61
DOI: 10.1055/s-2004-823139
In diesem Monat

© Georg Thieme Verlag Stuttgart · New York

Altbewährtes neu entdeckt - Aldosteronantagonisten und chronische Herzinsuffizienz

Well Tried but Newly Discovered - Aldosterone-Antagonists and Chronic Heart FailureA. Römer1 , H. Sievert1 , H.-J. Gilfrich1
  • 1CardioVasculäres Centrum Frankfurt, Innere Medizin I (Kardiologie/Angiologie/Intensivmedizin), Sankt Katharinen Krankenhaus, Frankfurt/Main (Leiter: Prof. Dr. H. Sievert)
Further Information

Publication History

Publication Date:
15 April 2004 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

In der neurohormonalen Theorie der Herzinsuffizienz spielt Aldosteron eine bedeutsame Rolle, durch seine Effekte auf die Endothelfunktion, auf die glatte Gefäßmuskulatur, auf die Adventitia, auf den PAI-1 (Plasminogen-Aktivator-Inhibitor-1) und auf die Fibrosierung des Myokards. Der therapeutische Ansatz mit Aldosteronantagonisten konnte sowohl tierexperimentell als auch in klinischen Studien (RALES, EPHESUS) eine günstige Wirkung auf die Herzinsuffizienzentwicklung zeigen sowie die Mortalität signifikant verbessern, wobei auf eine Niereninsuffizienz und engmaschige Kaliumkontrollen besonders geachtet werden muss.

Summary

Aldosterone has an important role in the neurohumoral pathophysiology of heart failure. This is caused by aldosterone effects on endothelium, smooth muscle cells, adventitia, PAI-1 and fibrosis of the myocardium. Experimental studies with aldosterone-antagonists were able to show a positive effect on the development of heart failure and large clinical trials could prove a significant reduction of mortality in patients with left ventricular dysfunction (RALES, EPHESUS). Close monitoring of potassium and renal failure is crucial for safe therapy with aldosterone-receptor-antagonists.

Key Words

aldosterone - heart failure - spironolactone - eplerenone - RALES - EPHESUS

Literatur

  • 1 Andreis PG, Tortorella C, Malendowicz LK. et al. . Endothelins stimulate aldosterone secretion from dispersed rat adrenal zona glomerulosa cells, acting through ETB receptors coupled with the phospholipase C-dependent signalling pathway.  Peptides. 2001;  22 117-122
    CrossrefPubMedSearch in Google Scholar
  • 2 Blacher J, Amah G, Girerd X. et al. . Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension.  Am J Hypertens. 1997;  10 1326-1334
    PubMedSearch in Google Scholar
  • 3 Brown NJ, Abbas A, Byrne D. et al. . Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.  Circulation. 2002;  105 304-309
    CrossrefPubMedSearch in Google Scholar
  • 4 Brown NJ, Agirbasli MA, Williams GH. et al. . Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.  Hypertension. 1998;  32 965-971
    CrossrefPubMedSearch in Google Scholar
  • 5 Brown NJ, Kim KS, Chen YQ. et al. . Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.  J Clin Endocrinol Metab. 2000;  85 336-344
    CrossrefPubMedSearch in Google Scholar
  • 6 Duprez DA, De ML Buyzere, Rietzschel ER. et al. . Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients [Comments].  Eur Heart J. 1998;  19 1371-1376
    CrossrefPubMedSearch in Google Scholar
  • 7 Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.  Circulation. 2000;  101 594-597
    CrossrefPubMedSearch in Google Scholar
  • 8 Funder JW. Aldosterone, salt and cardiac fibrosis.  Clin Exp Hypertens. 1997;  19 885-899
    PubMedSearch in Google Scholar
  • 9 Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance.  Annu Rev Med. 1997;  48 231-240
    CrossrefPubMedSearch in Google Scholar
  • 10 Hatakeyama H, Miyamori I, Fujita T. et al. . Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells.  J Biol Chem. 1994;  269 24316-24320
    PubMedSearch in Google Scholar
  • 11 Hinson JP, Kapas S. The role of endothelial cell products in the regulation of adrenocortical function: actions of endothelin, nitric oxide, adrenomedullin and PAMP.  Horm Metab Res. 1998;  30 334-340
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Klein KHW. Klinisch-experimentelle Untersuchungen über den Einfluss von Aldosteron auf Hämodynamik und Gerinnung.  Z Kreisl Forsch. 1963;  52 40-53
    PubMedSearch in Google Scholar
  • 13 Lombes M, Oblin ME, Gasc JM. et al. . Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor.  Circ Res. 1992;  71 503-510
    PubMedSearch in Google Scholar
  • 14 Luttun A, Dewerchin M, Collen D. et al. . The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.  Current Atherosclerosis Reports. 2000;  2 407-416
    PubMedSearch in Google Scholar
  • 15 MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.  Cardiovasc Res. 1997;  35 30-34
    CrossrefPubMedSearch in Google Scholar
  • 16 McKelvie RS, Yusuf S, Pericak D. et al. . Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study.  The RESOLVD Pilot Study Investigators [Comments]. Circulation. 1999;  100 1056-1064
    PubMedSearch in Google Scholar
  • 17 Modena MG, Aveta P, Menozzi A. et al. . Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.  Am Heart J. 2001;  141 41-46
    CrossrefPubMedSearch in Google Scholar
  • 18 Natarajan R, Lanting L, Bai W. et al. . The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells.  J Steroid Biochem Mol Biol. 1997;  61 47-53
    CrossrefPubMedSearch in Google Scholar
  • 19 Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone.  Eur J Contracept Reprod Health Care. 2000;  5 17-24
    PubMedSearch in Google Scholar
  • 20 Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.  Cardiovasc Drugs Ther. 1995;  9 145-149
    CrossrefPubMedSearch in Google Scholar
  • 21 Pitt B, Remme W, Zannad F. et al. . Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.  N Engl J Med. 2003;  348 1309-1321
    Search in Google Scholar
  • 22 Pitt B, Zannad F, Remme W. et al. . The effect of spironolactone on morbidity and mortality in patients with severe heart failure.  N Engl J Med. 1999;  341 709-717
    Search in Google Scholar
  • 23 Quinn S, Williams G. Regulation of aldosterone secretion.  Annu Rev Physiol. 1988;  50 409-426
    CrossrefPubMedSearch in Google Scholar
  • 24 Rajagopalan S, Duquaine D, King S. et al. . Mineralocorticoid receptor antagonism in experimental atherosclerosis.  Circulation. 2002;  105 2212-2216
    CrossrefPubMedSearch in Google Scholar
  • 25 Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage.  Curr Hypertension Repts. 2001;  3 240-248
    PubMedSearch in Google Scholar
  • 26 Safar ME. Epidemiological findings imply that goals for drug treatment of hypertension need to be revised.  Circulation. 2001;  103 1188-1190
    PubMedSearch in Google Scholar
  • 27 Safar ME. Mechanical factors predicting cardiovascular risk and drug treatment of hypertension.  J Hypertens. 2002;  20 349-352
    CrossrefPubMedSearch in Google Scholar
  • 28 Safar ME. Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors.  Curr Opin Nephrol Hypertens. 2001;  10 257-261
    PubMedSearch in Google Scholar
  • 29 Schepkens H, Vanholder R, Billiouw JM. et al. . Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.  Am J Med. 2001;  110 438-441
    CrossrefPubMedSearch in Google Scholar
  • 30 Silvestre JS, Robert V, Heymes C. et al. . Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation.  J Biol Chem. 1998;  273 4883-4891
    CrossrefPubMedSearch in Google Scholar
  • 31 Slight SH, Ganjam VK, Gomez-Sanchez CE. et al. . High affinity NAD(+)-dependent 11 beta-hydroxysteroid dehydrogenase in the human heart.  J Mol Cell Cardiol. 1996;  28 781-787
    CrossrefPubMedSearch in Google Scholar
  • 32 Somers MJ, Mavromatis K, Galis ZS. et al. . Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt.  Circulation. 2000;  101 1722-1728
    PubMedSearch in Google Scholar
  • 33 Staessen J, Lijnen P, Fagard R. et al. . Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.  J Endocrinol. 1981;  91 457-465
    PubMedSearch in Google Scholar
  • 34 Sun Y, Ratajska A, Zhou G. et al. . Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.  J Lab Clin Med. 1993;  122 395-403
    PubMedSearch in Google Scholar
  • 35 Taddei S, Virdis A, Mattei P. et al. . Vasodilation to acetylcholine in primary and secondary forms of human hypertension.  Hypertension. 1993;  21 929-933
    Search in Google Scholar
  • 36 Takeda Y, Yoneda T, Demura M. et al. . Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy.  Endocrinology. 2000;  141 1901-1904
    CrossrefPubMedSearch in Google Scholar
  • 37 Van Belle E, Bauters C, Wernert N. et al. . Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist.  Cardiovasc Res. 1995;  29 27-32
    CrossrefPubMedSearch in Google Scholar
  • 38 Weber KT. et al. . Mechanisms of disease: aldosterone in congestive heart failure.  N Engl J Med. 2001;  345 1689-1697
    CrossrefPubMedSearch in Google Scholar
  • 39 Wehling M, Neylon CB, Fullerton M. et al. . Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells.  Circ Res. 1995;  76 973-979
    PubMedSearch in Google Scholar
  • 40 Wehling M, Ulsenheimer A, Schneider M. et al. . Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium elevations by single cell imaging.  Biochem Biophys Res Commun. 1994;  204 475-481
    CrossrefPubMedSearch in Google Scholar
  • 41 Xiao F, Puddefoot JR, Vinson GP. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation.  J Endocrinol. 2000;  165 533-536
    CrossrefPubMedSearch in Google Scholar
  • 42 Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.  J Am Coll Cardiol. 2001;  37 1800-1807
    CrossrefPubMedSearch in Google Scholar
  • 43 Zannad F, Alla F, Dousset B. et al. . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES).  Circulation. 2000;  102 2700-2706
    PubMedSearch in Google Scholar
  • 44 Zhou G, Kandala JC, Tyagi SC. et al. . Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts.  Mol Cell Biochem. 1996;  154 171-178
    CrossrefPubMedSearch in Google Scholar

1 randomized evaluation of strategies for left ventricular dysfunction

2 randomized aldactone evaluation study

3 eplerenone post-acute myocardial infarction heart failure efficacy and survival trial

Anschrift für die Verfasser

Dr. A. Römer

CardioVasculäres Centrum Frankfurt

Innere Medizin I, Sankt Katharinen Krankenhaus

Seckbacher Landstr. 65

60389 Frankfurt